FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry and represents an injected composition in the form of a combined preparation for simultaneous, separate or successive application for the reduction, decrease or avoiding development of injection-initiated skin responses, in particular redness, ecchymosis, hematoma, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation, which contains a filler, capable of filling skin tissues, or botulinum toxin, an agonist of α-adrenergic receptors.
EFFECT: invention ensures reduction of skin responses, developing as a result of injection of fillers, capable of filling skin tissues.
14 cl, 2 dwg
